Regadenoson, sold under the brand name Lexiscan among others, is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging.[1] The selective nature of the drug makes it preferable to other stress agents such as adenosine, which are less selective and therefore cause more side-effects.
Regadenoson was approved by the United States Food and Drug Administration on April 10, 2008, and is marketed by Astellas Pharma under the tradename Lexiscan.[2] It is approved for use in the European Union and under the name of Rapiscan. It is marketed by GE Healthcare and is sold in both the United Kingdom and Germany. Regadenoson was approved for use in the European Union in September 2010.[3] It is available as a generic medication.[4]
Regadenoson has a two- to three-minute biological half-life, as compared with adenosine's ten-second half-life. As a result, regadenoson stress protocols use a single bolus, instead of the four- to six-minute continuous infusion that was needed with adenosine. Whereas the adenosine infusion is weight based (140 mcg/kg/minute), regadenoson is administered as a 0.4 mg/5mL preloaded syringe dose that is standard for all weights. Regadenoson stress tests are not affected by the presence of beta blockers, as regadenoson vasodilates via the adenosine pathway without stimulating beta adrenergic receptors.[citation needed]
Regadenoson can temporarily disrupt the integrity of the blood–brain barrier by inhibiting P-glycoprotein function.[5]
^Cerqueira MD (July 2004). "The future of pharmacologic stress: selective A2A adenosine receptor agonists". The American Journal of Cardiology. 94 (2A): 33D–40D, discussion 40D-42D. doi:10.1016/j.amjcard.2004.04.017. PMID 15261132.
^"CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM)" (PDF). Astellas Pharma US, Inc.
^"Rapiscan EPAR". European Medicines Agency. Retrieved 3 May 2020.
^"Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
^Kim DG, Bynoe MS (May 2016). "A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood–brain barrier". The Journal of Clinical Investigation. 126 (5): 1717–33. doi:10.1172/JCI76207. PMC 4855938. PMID 27043281.
Regadenoson, sold under the brand name Lexiscan among others, is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used...
treatments and concomitant diseases. Pharmacologic agents such as adenosine, regadenoson (Lexiscan), or dipyridamole is generally used when a patient cannot achieve...
are structurally similar to guanosine. Guanosine was also used to make regadenoson. Guanosine can be found in pancreas, clover, coffee plant, and pollen...
systemically administered corticosteroids. Aminophylline is used to reverse regadenoson, dipyridamole or adenosine based infusions during nuclear cardiology...
replaced by Flomaxtra XL, containing the same active ingredient Lexiscan (regadenoson injection) – Pharmacologic stress agent for myocardial perfusion scan...
Rapiscan may refer to: Rapiscan, a brand for the pharmaceutical drug regadenoson Rapiscan Systems, a manufacturer of metal detectors This disambiguation...
Global Information
(what is this?) (verify)